Self-Assembly Protein Nanogels for Safer Cancer Immunotherapy.

ABSTRACT: Soluble antigen-based cancer vaccines have poor retention in tissues along with suboptimal antigen processing by dendritic cells. Multiple booster doses are often needed, leading to dose-limiting systemic toxicity. A versatile, immunomodulatory, self-assembly protein nanogel vaccine is reported that induces robust immune cell response at lower antigen doses than soluble antigens, an important step towards biomaterials-based safer immunotherapy approaches.

SUBMITTER: Purwada A 

PROVIDER: S-EPMC5532174 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature